These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 7675648)

  • 1. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
    Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
    Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
    Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C
    J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Somatostatin receptor status in non-medullary thyroid carcinoma].
    Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
    Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.
    Meyer P; Bohnen NI; Barkan AL; Shapiro B
    Nuklearmedizin; 1999; 38(2):66-7. PubMed ID: 10100234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine tumors and somatostatin: imaging techniques.
    de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
    J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors.
    Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
    Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
    Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
    Legovini P; De Menis E; Billeci D; Conti B; Zoli P; Conte N
    J Endocrinol Invest; 1997; 20(7):424-8. PubMed ID: 9309542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin-receptor scintigraphy of subcutaneous and thyroid metastases from bronchial carcinoid.
    Krausz Y; Pfeffer MR; Glaser B; Lafair J
    J Nucl Med; 1996 Sep; 37(9):1537-9. PubMed ID: 8790214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relevance of somatostatin receptors in thyroid neoplasia.
    Ahlman H; Tisell LE; Wängberg B; Fjälling M; Forssell-Aronsson E; Kölby L; Nilsson O
    Yale J Biol Med; 1997; 70(5-6):523-33. PubMed ID: 9825479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
    Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
    J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebellar metastasis of papillary thyroid carcinoma detected with somatostatin receptor scintigraphy.
    Czepczyński R; Wyszomirska A; Gryczyńska M; Szczepanek-Parulska E; Ruchała M
    Endokrynol Pol; 2018; 69(1):24-27. PubMed ID: 29319129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
    Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
    Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
    Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide scintigraphy.
    Becker W; Schrell U; Buchfelder M; Hensen J; Wendler J; Gramatzki M; Wolf F
    Nuklearmedizin; 1995 Jun; 34(3):100-3. PubMed ID: 7630741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.
    Stokkel MP; Reigman HI; Verkooijen RB; Smit JW
    J Cancer Res Clin Oncol; 2003 May; 129(5):287-94. PubMed ID: 12750997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor scintigraphy of non-neuroendocrine malignancies with 111In-pentetreotide.
    Limouris GS; Rassidakis A; Kondi-Paphiti A; Triantafyllou N; Manetou A; Giannakopoulos V; Toubanakis N; Psyhojios I; Stavraka A; Vlahos L
    Anticancer Res; 1997; 17(3B):1593-7. PubMed ID: 9179200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
    Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
    J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.